Platform Application: CRISPR/Cas9 Delivery

About NTrans Technologies

NTrans Technologies is a private, pre-revenue biotech company pioneering a non-viral delivery platform for cell and gene therapies. Its core technology harnesses macropinocytosis, a natural cellular mechanism, to efficiently and safely deliver gene-editing complexes (RNPs) into patient cells ex vivo, with a focus on enhancing CAR-T therapies and other genetic medicines. The company, which is GMP-ready and emphasizes low manufacturing costs and high scalability, is supported by non-dilutive funding and strategic collaborations within the Dutch life sciences ecosystem. NTrans aims to solve key delivery challenges to unlock the full potential of next-generation genetic medicines.

Therapeutic Areas